PTCT$75.56
Chart
Performance
Key Stats
AI PTCT Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldPTC Therapeutics shows strong thematic potential in rare disease therapies with a solid product pipeline. Fundamentally, the company faces profitability challenges and high leverage, while technical indicators suggest a cautious near-term outlook.
Thematic
The company is well-positioned in biopharmaceuticals targeting rare disorders, with several marketed products and an innovative pipeline focused on gene therapy and rare diseases.
Fundamental
Current fundamentals show a company struggling with negative earnings, high debt levels, and negative equity despite positive recent revenue growth and improving earnings per share.
Technical
Technical indicators show mixed signals with near-term oscillators suggesting caution, but moving averages indicate support around current price levels.
| Factor | Score |
|---|---|
| Rare Disease Therapeutics Focus | 90 |
| Product Pipeline Strength | 80 |
| Collaborations and Licensing | 75 |
| Market Dynamics | 70 |
| Regulatory Environment | 65 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 35 |
| Growth | 80 |
| Balance Sheet Health | 25 |
| Cash Flow | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 65 |
| Momentum | 60 |
| Volume Confirmation | 50 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strong Recent Earnings Beat
The company reported a Q2 2025 EPS of 10.04 versus an estimate of -0.21, a massive upside surprise indicating a significant positive earnings momentum.
Robust One-Year Performance
The stock price increased by 46.72% over the past year, demonstrating strong investor confidence and market outperformance.
Bearish Points (6)
Persistently Negative Net Income in Most Historical Periods
Despite recent earnings beats, the company recorded significant net losses in recent years and quarters, such as -363 million net income in 2024 Q4 and -626 million in 2023 Q4, reflecting ongoing profitability challenges.
Elevated Debt Levels with Negative Equity
The company reported over 2.47 billion in debt at 2024 Q4 and negative total equity (-1.1 billion), posing financial risk due to high leverage and solvency concerns.
Calendar
August 2025
8
Next Earnings Date
H: $-1.08
A: $-1.19
L: $-1.27
H: 198.50M
A: 173.01M
L: 146.70M
Profile
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Seasonals
Price Target
62.81 USD
The 39 analysts offering 1 year price forecasts for PTCT have a max estimate of 112.00 and a min estimate of 40.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
The given company itself, a biotechnology company focused on rare disorders.
Weight: 90
Biotech company focusing on rare genetic diseases, closely related to PTCT's therapy focus.
Weight: 88
Specializes in rare neuromuscular diseases; shares focus on genetic therapies.
Weight: 85
Pioneers in gene editing technologies, relevant to PTC Therapeutics' gene therapy approaches.